MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Amphastar Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

26.4 -2.15

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.38

Max

26.86

Galvenie mērījumi

By Trading Economics

Ienākumi

5.7M

31M

Pārdošana

3.9M

174M

P/E

Sektora vidējais

10.045

35.739

Peļņas marža

17.791

Darbinieki

2,028

EBITDA

9.5M

62M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+17.82% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

243M

1.3B

Iepriekšējā atvēršanas cena

28.55

Iepriekšējā slēgšanas cena

26.4

Ziņu noskaņojums

By Acuity

50%

50%

149 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. okt. 23:30 UTC

Karstas akcijas

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2025. g. 2. okt. 21:21 UTC

Peļņas

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

2025. g. 3. okt. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2025. g. 2. okt. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2025. g. 2. okt. 23:39 UTC

Tirgus saruna

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2025. g. 2. okt. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2025. g. 2. okt. 23:00 UTC

Tirgus saruna

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Scales's JV Buyout Lauded by Bull -- Market Talk

2025. g. 2. okt. 22:54 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2025. g. 2. okt. 22:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. okt. 21:17 UTC

Iegādes, apvienošanās, pārņemšana

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2025. g. 2. okt. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 2. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 2. okt. 20:49 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2025. g. 2. okt. 20:00 UTC

Iegādes, apvienošanās, pārņemšana

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2025. g. 2. okt. 19:20 UTC

Tirgus saruna

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2025. g. 2. okt. 19:10 UTC

Tirgus saruna

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2025. g. 2. okt. 19:04 UTC

Tirgus saruna

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2025. g. 2. okt. 18:46 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2025. g. 2. okt. 18:45 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2025. g. 2. okt. 18:44 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2025. g. 2. okt. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Salīdzinājums

Cenas izmaiņa

Amphastar Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

17.82% augšup

Prognoze 12 mēnešiem

Vidējais 31.8 USD  17.82%

Augstākais 36 USD

Zemākais 25 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Amphastar Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

23.91 / 25.04Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

149 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat